Advancing GT201 by Enhancing TIL Persistence, Demonstrating Clinical Activity & Uncovering Biomarker Insights
- Showcasing product design, mechanism of action, and preclinical data demonstrating enhanced TIL persistence and tumor cytotoxicity with reduced IL-2 dependency
- Demonstrating safety and preliminary efficacy data from approximately 10 solid tumor patients, including at least one complete response and multiple partial responses
- Deep diving into analyses leveraging single-cell profiling of longitudinal patient samples with TCR tracking to optimize manufacturing process and guide biomarker discovery